Monitoring Disease Burden and Biology Using Tumor Cell

Recruiting

99 years or below

All

1 Location

Brief description of study

Blood is an easily accessible source of tumor cell free (cf) DNA. Both normal and malignant cells shed DNA into the circulation, and advanced genomics technologies can analyze tumor cfDNA, making blood a source of real-time genomic tumor profiling. For ccRCC patients, peripheral blood will be obtained as part of routine clinical care. Blood will be collected at baseline, first restaging scan, second restaging scan and at time of progression or approximately 2 years, whichever occurs first.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 08 Jun 2022. Study ID: 849801

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

Brief description of study

Eligibility of study

Find a site

Interested in the study